Showing results (381-390 of 503) with videos related to
Sort By:
Pageof 51
The American Journal of Pathology|September 21, 2023
Tumor-Infiltrating Lymphocyte Recognition in Primary Melanoma by Deep Learning Convolutional Neural NetworkFilippo Ugolini, Francesco De Logu, Luigi Francesco Iannone, et al.Biomedicines|October 27, 2022
Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective StudyMartina Burlando, Gabriella Fabbrocini, Claudio Marasca, et al.Critical Reviews in Oncology/Hematology|July 13, 2023
Long-term strategies for management of advanced basal cell carcinoma with hedgehog inhibitorsPaolo Bossi, Paolo A Ascierto, Nicole Basset-Seguin, et al.Dermatologic Therapy|April 6, 2022
Risankizumab for the treatment of moderate-to-severe psoriasis: A multicenter, retrospective, 1 year real-life studyGiacomo Caldarola, Arianna Zangrilli, Nicoletta Bernardini, et al.BMC Cancer|November 13, 2024
Interim analysis of the multinational, post-authorization safety study (NISSO) to assess the long-term safety of sonidegib in patients with locally advanced basal cell carcinomaRalf Gutzmer, Ulrike Leiter, Peter Mohr, et al.Diagnostics (Basel, Switzerland)|December 9, 2023
Line-Field Confocal Optical Coherence Tomography Evaluation of Eyelid Skin LesionsAlessandro Di Stefani, Simone Cappilli, Giovanni Cuffaro, et al.Journal of the American Academy of Dermatology|July 21, 2022
Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trialAndrew Blauvelt, Richard G Langley, Jean-Philippe Lacour, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|May 20, 2025
A clinical-dermoscopic risk scoring model for early melanoma of the soles: The iDScore_plantarLinda Tognetti, Sofia Lo Conte, Simone Leonardelli, et al.Frontiers in Oncology|February 27, 2023
Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative studyPaolo A Ascierto, Eleonora Cioli, Vanna Chiarion-Sileni, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|August 1, 2024
International consensus on methotrexate dosing for patients with atopic dermatitis: An eDelphi studyAnouk G M Caron, Astrid M van Huizen, Annelie A H Musters, et al.Pageof 51